In the BioHarmony Drug Report Database

"Preview" Icon

Nebivolol

Bystolic (nebivolol) is a small molecule pharmaceutical. Nebivolol was first approved as Bystolic on 2007-12-17. It is used to treat malignant hypertension in the USA. It is known to target beta-3 adrenergic receptor, beta-2 adrenergic receptor, and beta-1 adrenergic receptor. Bystolic’s patent is valid until 2021-12-17 (FDA).

 

Trade Name

 

Bystolic
 

Common Name

 

nebivolol
 

ChEMBL ID

 

CHEMBL434394
 

Indication

 

malignant hypertension
 

Drug Class

 

Beta-blockers (propranolol type)

Image (chem structure or protein)

Nebivolol structure rendering